Results 71 to 80 of about 2,198 (193)

FDA Approves Selpercatinib; Pralsetinib May Soon Follow [PDF]

Cancer Discovery, 2020
Abstract The FDA has greenlighted selpercatinib, the first targeted therapy for RET-altered non–small cell lung cancer (NSCLC) and certain types of thyroid cancer. Another RET inhibitor, pralsetinib, has been submitted for approval to treat NSCLC. Both drugs have shown effectiveness in treating brain metastases.
openaire   +2 more sources

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

Frontiers in Oncology, 2022
During the last two decades, kinase inhibitors have become the major drug class for targeted cancer therapy. Although the number of approved kinase inhibitors increases rapidly, comprehensive in vitro profiling and comparison of inhibitor activities is ...
Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus, Martine B. W. Prinsen, Yvonne Grobben, Tessa J. J. de Bitter, Antoon M. van Doornmalen, Janneke J. T. M. Melis, Joost C. M. Uitdehaag, Yugo Narumi, Yusuke Kawase, Jeroen A. D. M. de Roos, Nicole Willemsen-Seegers, Guido J. R. Zaman   +13 more
doaj   +1 more source

Epigenetic Regulation of Autophagy in Breast Cancer: Implications for Biomarker Discovery and Personalized Therapy

Cancer Reports, Volume 8, Issue 12, December 2025.
ABSTRACT Background Breast cancer remains one of the most common and lethal malignancies among women. Despite advanced targeted therapies and precision medicine, therapeutic resistance continues to undermine durable clinical responses. Increasing evidence links epigenetic dysregulation and autophagy as central contributors to breast cancer progression,
Bushra Faryal
wiley   +1 more source

Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD) [PDF]

, 2022
Background: The ARROW study is assessing the anti-tumour activity of pralsetinib, a highly-selective RET inhibitor in advanced solid tumours, including RET fusion+ NSCLC.
Arndorfer, S. M, Cappuzzo, F., Gadgeel, Shirish M, Gainor, J., Garralda, E., Kim, D. W, Lee, D. H, Lopes, G., Mazieres, J., Miller, S., Noe, J., Nowicka, M., Rahman, A., Subbiah, V., Trinh, H., Zhang, Q., Zhu, V.   +16 more
core   +1 more source

Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management

MedComm, Volume 6, Issue 11, November 2025.
Thyroid cancer risk is influenced by both genetic and modifiable factors, including mutations, radiation exposure, lifestyle, and pre‐existing benign conditions. Diagnosis involves physical exams, ultrasound, scintigraphy, laboratory tests, and fine‐needle aspiration biopsy (FNAB).
Yu‐Dong Li, Qing‐Yao Ye, Yan‐Xing Chen, Xia‐Rong Hu   +3 more
wiley   +1 more source

Update on International Medical Taxonomies of Biomarkers and Their Applications in Management of Thyroid Cancers

Diagnostics, 2022
Biomarkers (BMs) are medical signs which can be precisely measured and reproduced. Mainly, BMs provide information on the likely disease which can occur in an individual. On the other hand, BMs also signal disease recurrence in patients receiving therapy.
Maria Trovato
doaj   +1 more source

Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation

The Oncologist, 2023
Abstract Triple-negative breast cancers (TNBC) represent a pathological subtype of breast cancer, which are characterized by strong invasiveness, high metastasis rate, low survival rate, and poor prognosis, especially in patients who have developed resistance to multiline treatments.
Jing Zhao, Wei Xu, Xiaoli Zhuo, Lei Liu, Junlei Zhang, Fengxian Jiang, Yanru Shen, Yan Lei, Dongsheng Hou, Xiaoyan Lin, Cuiyan Wang, Guobin Fu   +11 more
openaire   +2 more sources

1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC) [PDF]

, 2022
Min Hu, V. Subbiah, Aaron S. Mansfield, Matthew H. Taylor, M.H.H. Schuler, Viola W. Zhu, Julien Hadoux, Giuseppe Curigliano, Lori J. Wirth, Elena Garralda, Douglas R. Adkins, Y. Godbert, M-J. Ahn, P. Cassier, Byoung Chul Cho, C-C. Lin, Teresa Barata, Alena Zalutskaya, Astrid Scalori, Marcia S. Brose   +19 more
openalex   +1 more source

Comprehensive Genomic Profiling in Advanced Non‐Small Cell Lung Cancer: A Real‐World Cohort Study in Finland

Cancer Medicine, Volume 14, Issue 19, October 2025.
ABSTRACT Background Non‐small cell lung cancer (NSCLC) is a disease with a low survival rate and poor prognosis. Targeted therapies have improved treatment outcomes as driver mutations have been identified, especially in adenocarcinomas. Comprehensive genomic profiling (CGP) provides insights into the genetic mutation profile of cancer and helps ...
Kirsi Hormalainen, Kaisa Marttila, Matti Nykter, Toomas Uibu, Jarkko Ahvonen, Vidal Fey, Mauri Keinänen, Maarit Bärlund, Arja Jukkola   +8 more
wiley   +1 more source

Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research

MedComm, Volume 6, Issue 10, October 2025.
In TME, undetectable DCCs (panel A) join with a low tumor burden along with low immune suppression, that favor successful immune manipulation through immune suppression inhibiting immune‐therapy. This moves the immune balance toward the immune response and likely makes more stable the dormant state of DCCs in the unstable metastatic niche and/or allows
Andrea Nicolini, Paola Ferrari, Roberto Silvestri, Dario A. Bini   +3 more
wiley   +1 more source